Long-term extension study of balinatunfib in Crohn's disease or ulcerative colitis

Phase 2, open-label trial of balinatunfib in Crohn's disease and autoimmune colitis (2 arms), sponsored by Sanofi. Primary endpoints: Number of participants with Crohn's disease with treatment-emergent adverse events, serious adverse events, and adverse events of special interest and Number of participants with ulcerative colitis with treatment-emergent adverse events, serious adverse events, and adverse events of special interest. Started May 2026; status: completed.